Cancer is a leading cause of death and poor quality of life globally. Even though several
strategies are devised to reduce deaths, reduce chronic pain and improve the quality of life …

The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The
patients present an advanced stage at diagnosis. This heterogeneous disease has …

Over the past decade, the development of 'simple'blood tests that enable cancer screening,
diagnosis or monitoring and facilitate the design of personalized therapies without the need …

Introduction: Urine is a highly desirable biospecimen for biomarker analysis because it can
be collected recurrently by non-invasive techniques, in relatively large volumes. Urine …

Serum is an ideal biological sample that contains an archive of information due to the
presence of a variety of proteins released by diseased tissue, and serum proteomics has …

The prominent discrepancy between the significant investment towards plasma biomarker
discovery and the very low number of biomarkers currently in clinical use stresses the need …

Many low-abundance biomarkers for early detection of cancer and other diseases are
invisible to mass spectrometry because they exist in body fluids in very low concentrations …

Urological malignancies are a major cause of morbidity and mortality worldwide. Advances
in early detection, diagnosis, prognosis and prediction of treatment response can …

In the past decade, there has been an increasing interest in applying proteomics to assist in
understanding the pathogenesis of ovarian cancer, elucidating the mechanism of drug …

Current protocols for the screening of prostate cancer cannot accurately discriminate
clinically indolent tumors from more aggressive ones. One reliable indicator of outcome has …